New Canadian Association of Gastroenterology Clinical Practice Guidelines for the Management of IBS– April 2019.

The Journal of the Canadian Association of Gastroenterology has newly published guidelines for the management of irritable bowel syndrome (IBS) in adults in its April 2019 issue. Twelve named authors from the fields of gastroenterology,  health psychology and primary care, represent six Canadian universities with one author currently unaffiliated. These are McMaster University, the University

International Foundation for Functional Gastrointestinal Disorders (IFFGD) Seeking Volunteers for New Patient Panel

The International Foundation for Functional Gastrointestinal Disorders (IFFGD) is an established, reputable U.S. based 501c3 not-for-profit organization/charity focused on irritable bowel syndrome (IBS) and related functional gastrointestinal disorders, also known as disorders of gut-brain interaction. IFFGD was founded in 1991 by an FGID-affected family and continues to have people with FGIDs or family members/supporters among

DNA Variants on Chromosome 9 May Be Associated with Increased Risk of IBS in Some Women

In April 2018, the journal Gastroenterology  reported that an international collaboration of researchers headed by the Karolinska Institutet in Sweden, has identified several DNA variants on Chromosome 9 that may be associated with higher risk of IBS in women, particularly IBS with constipation. This possible correlation was not found in men. The identified chromosomal regions

Gastrointestinal Society (Canada) Releases 2018 IBS Global Impact Report

In April 2018, in time for IBS Awareness Month, the Gastrointestinal Society in Canada released a 38 page 2018 IBS Global Impact Report, which is available for download on its website.  This report was funded and facilitated by the international pharmaceutical company Allergan, and overseen by a steering committee composed of Maura Corsetti, MD of

U.S. Food and Drug Administration (FDA) Approves Plecanatide (Trulance) for Use in IBS with Constipation, January 2018

In January 2018, plecanatide, also known by the brand name Trulance, and previously available in the United States for use in chronic idiopathic constipation, was approved by the U.S. Food and Drug Administration (FDA) for treatment of irritable bowel syndrome with constipation (IBS-C). See this link. https://www.healio.com/gastroenterology/irritable-bowel-syndrome/news/online/%7B0aa46942-f0d1-4b90-a703-335e5878dec4%7D/fda-approves-trulance-for-ibs-c Updated May 2018

Research Links Gut Microbiome Changes to Brain Structure in IBS

One of the interesting and groundbreaking articles presented this year at Digestive Disease Week, an annual international gastroenterology professional conference in May 2017 is a collaboration of 14 researchers from UCLA, Texas Children’s Microbiome Center and Baylor College of Medicine, and the Washington University School of Medicine in St, Louis, Missouri. The authors confirmed the